Media Room
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
April 24, 2026
Press Release: Sanofi successfully prices 2.3 billion of bond issue
April 24, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
April 23, 2026
Press Release: Q1 2026: double-digit sales and business EPS growth
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
October 2025
Annual Report on Form 20-F
Annual Report on Form 20-F 2025
July 2025
Half-year Financial Reports
Half Year 2025 Financial Report
July 2025
Half-year Financial Reports
Half year 2025 financial report XBRL package
September 2024
Annual Report on Form 20-F
Annual Report on Form 20-F 2024